Skip to main content
. 2022 Mar 10;12:852859. doi: 10.3389/fonc.2022.852859

Figure 4.

Figure 4

Checkpoint kinase inhibition as an effective antitumor strategy in preclinical tumor models of TSC2 loss. (A) Tumor volume of 105K xenografts in BALB/c nude mice treated once daily for 28 days with either vehicle (n = 14) or AZD7762 (12.5 mg/kg, n = 14); data presented as mean ± 95% confidence interval. (B–D) Eight-month-old A/J Tsc2 +/- mice were treated daily with either vehicle (n = 10) or AZD7762 (12.5 mg/kg, n = 10) for 28 days; each treatment group had five male and five female mice. Data presented as mean ± 95% confidence interval and analyzed by one way ANOVA (*p < 0.05; **p < 0.01). (E) H&E-stained tissue of kidney sections from each indicated treatment group showing large cystadenoma lesion (vehicle) and cleared cyst (AZD7762).